• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

撤稿：罗沙司他联合口服铁剂治疗老年慢性肾脏病合并贫血的疗效及机制

Retracted: Efficacy and Mechanism of Roxadustat plus Oral Iron in the Treatment of Elderly Chronic Kidney Disease with Anemia.

作者信息

And Alternative Medicine Evidence-Based Complementary

出版信息

Evid Based Complement Alternat Med. 2023 Jun 21;2023:9823823. doi: 10.1155/2023/9823823. eCollection 2023.

DOI:10.1155/2023/9823823
PMID:37387946
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10307336/
Abstract

[This retracts the article DOI: 10.1155/2022/9192655.].

摘要

[本文撤回文章DOI: 10.1155/2022/9192655。]

相似文献

1
Retracted: Efficacy and Mechanism of Roxadustat plus Oral Iron in the Treatment of Elderly Chronic Kidney Disease with Anemia.撤稿：罗沙司他联合口服铁剂治疗老年慢性肾脏病合并贫血的疗效及机制
Evid Based Complement Alternat Med. 2023 Jun 21;2023:9823823. doi: 10.1155/2023/9823823. eCollection 2023.
2
Efficacy and Mechanism of Roxadustat plus Oral Iron in the Treatment of Elderly Chronic Kidney Disease with Anemia.罗沙司他联合口服铁剂治疗老年慢性肾脏病伴贫血的疗效及机制
Evid Based Complement Alternat Med. 2022 Jun 25;2022:9192655. doi: 10.1155/2022/9192655. eCollection 2022.
3
The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review.罗沙司他治疗肾病患者贫血的疗效和安全性：一项荟萃分析和系统评价。
Int Urol Nephrol. 2021 May;53(5):985-997. doi: 10.1007/s11255-020-02693-7. Epub 2021 Jan 3.
4
The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.罗沙司他治疗透析依赖性慢性肾脏病患者贫血的疗效和安全性：系统评价和荟萃分析。
Ren Fail. 2023 Dec;45(1):2195011. doi: 10.1080/0886022X.2023.2195011.
5
Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.日本血液透析慢性肾脏病贫血患者罗沙司他的 3 期、随机、双盲、阳性对照（达贝泊汀α）研究。
J Am Soc Nephrol. 2020 Jul;31(7):1628-1639. doi: 10.1681/ASN.2019060623. Epub 2020 Jun 3.
6
A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.一项评估罗沙司他间歇口服给药治疗未接受透析的非透析慢性肾脏病且对红细胞生成刺激剂初治的日本贫血患者的 3 期、多中心、随机、双盲、开放性研究
Nephron. 2020;144(8):372-382. doi: 10.1159/000508100. Epub 2020 Jun 24.
7
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.罗沙司他治疗未接受透析的肾病患者的贫血。
N Engl J Med. 2019 Sep 12;381(11):1001-1010. doi: 10.1056/NEJMoa1813599. Epub 2019 Jul 24.
8
Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.缺氧诱导因子脯氨酰羟化酶抑制剂罗沙司他的非临床特征：慢性肾脏病贫血的一种新治疗方法。
J Pharmacol Exp Ther. 2020 Aug;374(2):342-353. doi: 10.1124/jpet.120.265181. Epub 2020 Jun 2.
9
The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis.罗沙司他治疗慢性肾脏病患者贫血的疗效与安全性：一项荟萃分析
Front Pharmacol. 2022 Apr 26;13:779694. doi: 10.3389/fphar.2022.779694. eCollection 2022.
10
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.口服低氧诱导因子脯氨酰羟化酶抑制剂罗沙司他（FG-4592）用于治疗慢性肾脏病患者的贫血
Clin J Am Soc Nephrol. 2016 Jun 6;11(6):982-991. doi: 10.2215/CJN.06890615. Epub 2016 Apr 19.

本文引用的文献

1
Efficacy and Mechanism of Roxadustat plus Oral Iron in the Treatment of Elderly Chronic Kidney Disease with Anemia.罗沙司他联合口服铁剂治疗老年慢性肾脏病伴贫血的疗效及机制
Evid Based Complement Alternat Med. 2022 Jun 25;2022:9192655. doi: 10.1155/2022/9192655. eCollection 2022.